Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases

Figures & data

Table I. Univariate analysis of PTR in patients.

Variables	No.	PTR	Non-PTR	P value
Total, n (%)	108	56(51.85)	52(48.15)
Gender, n (%)				.492
Female	70	38(54.3)	32(45.7)
Male	38	18(47.4)	20(52.6)
Age(y), mean±SD				.266
		39.75 ± 11.63	37.23 ± 11.78
Diagnosis, n (%)				.703
AA	7	5(71.4)	2(28.6)
MDS	19	11(57.9)	8(42.1)
AML	55	26(47.3)	29(52.7)
ALL	15	7(46.7)	8(53.3)
Others	12	7(58.3)	5(41.7)
Pregnancy, n (%)				.086
No	6	1(16.7)	5(83.3)
Yes	64	37(57.8)	27(42.2)
ABO blood group, n (%)				.068
O	35	15(42.9)	20(57.1)
A	34	15(44.1)	19(55.9)
B	31	19(61.3)	12(38.7)
AB	8	7(87.5)	1(12.5)
PLT(×10^9/L), median (IQR)				.323
		48.50(2.75–79.25)	54.50(28.75–98.25)
Splenomegaly, n (%)				<.001
Yes	28	25(89.3)	3(1.7)
No	80	31(38.8)	49(61.3)

Figure 1. Distribution of gene mutations.

Figure 2. (a) Comparison of preliminary antibody screening values between the two groups. (b) Comparison of the frequency of HLA-I antibodies between the two groups. (c) Comparison of the frequency of HLA-II antibodies between the two groups. (d) Comparison of the number of patients with positive HLA-I and II antibodies between the two groups.

Table II. The distribution of antibodies in patients.

Variables	No.	PTR	Non-PTR	P value
Screening value, median (IQR)				.0008
		73.50(47.50–98.75)	4.50(34.00–85.75)
HLA-I, n (%)				.002
Negative	52	20(38.5)	32(61.5)
Positive	8	2(25.0)	6(75.0)
Strongly positive	39	28(71.8)	11(28.2)
HLA-I, n (%)				.0158
Negative	52	20(38.5)	32(61.5)
Positive	47	30(63.8)	17(36.2)
HLA-II, n (%)				.008
Negative	64	26(4.6)	38(59.4)
Positive	7	3(42.9)	4(57.1)
Strongly positive	28	21(75.0)	7(25.0)
HLA-II, n (%)				.0113
Negative	64	26(4.63)	38(59.38)
Positive	35	24(68.57)	11(31.43)
HLA-I and HLA-II, n (%)				.0004
Both positive	31	24(77.42)	7(22.58)
not	68	26(38.24)	42(61.76)

Table III. Multivariate logistic analysis.

Variables	Odds ratios (95% CI)	P value
Splenomegaly	26.98(4.641–156.861)	<.001
Pregnancy
one time	0.18(0.008–4.163)	.286
two times	1.88(0.385–8.917)	.428
three times	3.52(0.576–21.511)	.173
RUNX	2.20(0.167–28.956)	.549
JAK	17.32(1.454–206.450)	.024
DNMT	0.14(0.012–1.516)	.105
KMT2	2.04(0.290–14.303)	.474
Blood type	-	-
Anti-HLA-I	1.39(0.299–6.445)	.675
Anti-HLA-II	2.78(0.564–13.680)	.209
Malignant disease	2.60(0.498–13.630)	.257

Figure 3. (a) Kaplan–Meier curves for overall survival in the two groups. (b) Kaplan–Meier curves for relapse-free survival in the two groups.

Figure 4. Comparison of platelet transfusion requirements during transplantation.

Figure 5. Trends in platelet levels after transplantation in the two groups.

Figure 6. Multivariate COX regression analysis.

Data availability statement

If requested, the original data presented in this paper will be available through the corresponding author [email protected].